GAITHERSBURG, Md., July 26 /PRNewswire-FirstCall/ -- Digene Corporation today announced it intends to announce financial results for the fiscal 2006 fourth quarter and twelve months ended June 30, 2006 at the close of market on Tuesday, August 8, 2006.
Digene will host a conference call, which will be broadcast live over the Internet on Tuesday, August 8, 2006 at 4:30 p.m. EDT. The broadcast will be hosted on the Company's website located at http://www.digene.com.
Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.
The online archive of the broadcast will be available within two hours of the live call and can be accessed through November 8, 2006, by dialing (800) 294-4340 or (402) 220-9772.
About Digene
Digene Corporation , based in Gaithersburg, MD, develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases -- with a focus on women's cancers and infectious diseases. The company's hc2 High-Risk HPV DNA Test(R) is the only test for human papillomavirus approved by the FDA, and is approved for both follow-up evaluation in women with inconclusive Pap results and for primary adjunctive screening with the Pap test in women age 30 and older. For primary adjunctive screening, it is marketed as both The Digene HPV Test and the DNAwithPap(R) Test. These brand names do not refer to the Digene product that tests for several types of the virus commonly referred to as "low-risk HPV," which are not associated with cervical cancer. For more information, visit http://www.thehpvtest.com. Digene's product portfolio also includes DNA tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses. For more information, visit the company's Web site, http://www.digene.com. Investors also may contact Charles Fleischman at (301) 944-7000; journalists may contact Pam Rasmussen, (301) 944-7196. Digene(R), Hybrid Capture(R), hc2 High-Risk HPV DNA Test(R) and DNAwithPap(R) are registered trademarks of Digene Corporation.
Digene CorporationCONTACT: Charles M. Fleischman, President of Digene Corporation,+1-301-944-7000; or Investors - Jonathan Birt of Financial Dynamics,+1-212-850-5634; or Media - Pam Rasmussen of Digene, +1-301-944-7196; orSean Leous of Financial Dynamics, +1-212-850-5600
Web site: http://www.digene.com/
